KITLG and Alzheimer disease: Through a network pharmacology analysis, we identified significant intersections between SCF and AD-related targets, emphasizing critical connections such as gomisin A, gomisin C, schisandrin A, schisandrin B, and schisandrin C. Our experimental validation demonstrated SCF’s ability to mitigate the dysregulation in glucose and lipid metabolism, oxidative stress, neuroinflammation, and neuronal cell death associated with AD in rats injected with Aβ (25-35).